Q1 25 EPS
$-0.10
BEAT +13.04%
Est. $-0.12
Q1 25 Revenue
$9.4M
BEAT +1.04%
Est. $9.3M
vs S&P Since Q1 25
+216.5%
BEATING MARKET
APYX +253.4% vs S&P +36.8%
Market Reaction
Did APYX Beat Earnings? Q1 2025 Results
Apyx Medical posted a narrower-than-expected loss in Q1 2025, delivering an earnings beat even as revenue slipped year-over-year, with aggressive cost discipline emerging as the defining story of the quarter. The medical device maker reported revenue… Read more Apyx Medical posted a narrower-than-expected loss in Q1 2025, delivering an earnings beat even as revenue slipped year-over-year, with aggressive cost discipline emerging as the defining story of the quarter. The medical device maker reported revenue of $9.43 million, down 8% from a year ago but edging past the $9.33 million consensus estimate by 1.04%, while its loss per share of $0.10 beat the $0.12 estimate by 13.04%. The headline decline was almost entirely driven by a 45% collapse in OEM segment revenue to $1.54 million, which obscured a 6% gain in the core Advanced Energy segment to $7.89 million, fueled by strong domestic generator and handpiece sales. The more compelling development was a $3.80 million reduction in total operating expenses, which helped cut the net loss nearly in half to $4.15 million. Management reaffirmed full-year 2025 revenue guidance of $47.60 million to $49.00 million, and the company has since received FDA clearance for its AYON Body Contouring System, setting up a commercial launch in the second half of 2025 as a potential growth catalyst.
Key Takeaways
- • Strong domestic generator unit sales driving Advanced Energy growth
- • U.S. single-use handpiece revenue grew 14% year-over-year
- • Cost-cutting measures from Q4 2024 reduced operating expenses by $3.8 million
- • Improved gross margin to 60% from 58% due to favorable product and geographic mix
- • OEM revenue declined 45% due to decreased sales volume to existing customers
APYX YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
APYX Revenue by Segment
With YoY comparisons, source: SEC Filings
APYX Revenue by Geography
With YoY comparisons, source: SEC Filings
“We have made steady progress executing against our commercial strategy to position Apyx as the leader in surgical aesthetics. We believe Renuvion, which is the only FDA-cleared device for use after liposuction, is positioned to be the standard-of-care for the rapidly growing patient population on GLP-1 drugs that choose to address their loose skin post-weight loss. This is an exciting new opportunity within the industry that we believe offers our company tremendous opportunities for future growth.”
— Charlie Goodwin, Q1 2025 Earnings Press Release
APYX Earnings Trends
APYX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
APYX EPS Trend
Earnings per share: estimate vs actual
APYX Revenue Trend
Quarterly revenue: estimate vs actual
APYX Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.08 | $-0.07 | +14.63% | $13.9M | +5.38% |
| Q1 26 BEAT | $-0.10 | $-0.05 | +50.00% | $12.5M | +9.13% |
| Q4 25 BEAT FY | $-0.06 | $-0.03 | +46.43% | $19.2M | +0.21% |
| FY Full Year | $-0.30 | $-0.27 | +11.18% | $52.8M | +1.19% |
| Q3 25 BEAT | $-0.10 | $-0.05 | +51.22% | $12.9M | +7.30% |
| Q2 25 BEAT | $-0.09 | $-0.09 | +0.00% | $11.4M | -2.79% |
| Q1 25 BEAT | $-0.12 | $-0.10 | +13.04% | $9.4M | +1.04% |